SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) together with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical firm centered on revolutionizing the remedy of neurodegenerative illness, at present introduced that it’ll report topline outcomes of the CNM-Au8® routine of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene’s administration staff will host a convention name and webcast to talk about the outcomes.
Conference Call and Webcast Details
Time and Date: 8:30 a.m. EDT on Oct. 3, 2022
Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)
Conference ID: 5318408
Webcast Link
A stay audio webcast may be accessed by visiting the Investors part of the Company’s web site on the Events web page. An archived webcast will probably be out there on the web site roughly two hours after the occasion.
About CNM-Au8®
CNM-Au8 is Clene’s lead asset in mid- and late-stage medical improvement for the remedy of a number of sclerosis and amyotrophic lateral sclerosis. An oral suspension of gold nanocrystals, CNM-Au8 was developed to shield neuronal well being and performance by growing vitality manufacturing and utilization. The catalytically lively nanocrystals of CNM-Au8 drive crucial mobile vitality producing reactions that allow neuroprotection and remyelination by growing neuronal and glial resilience to disease-relevant stressors. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc.
About Clene
Clene is a clinical-stage biopharmaceutical firm centered on revolutionizing the remedy of neurodegenerative illness by concentrating on energetic failure, an underlying reason for many neurological ailments. The firm relies in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For extra info, please go to www.clene.com or observe us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press launch incorporates “forward-looking statements” inside the which means of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, that are supposed to be lined by the “safe harbor” provisions created by these legal guidelines. Clene’s forward-looking statements embody, however are usually not restricted to, statements relating to our or our administration staff’s expectations, hopes, beliefs, intentions or methods relating to our future operations. In addition, any statements that refer to projections, forecasts or different characterizations of future occasions or circumstances, together with any underlying assumptions, are forward-looking statements. The phrases “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and related expressions could determine forward-looking statements, however the absence of those phrases doesn’t imply {that a} assertion shouldn’t be forward-looking. These forward-looking statements characterize our views as of the date of this press launch and contain quite a few judgments, dangers and uncertainties. We anticipate that subsequent occasions and developments will trigger our views to change. We undertake no obligation to replace forward-looking statements to replicate occasions or circumstances after the date they have been made, whether or not on account of new info, future occasions or in any other case, besides as could also be required below relevant securities legal guidelines. Accordingly, forward-looking statements shouldn’t be relied upon as representing our views as of any subsequent date. As a results of quite a few identified and unknown dangers and uncertainties, our precise outcomes or efficiency could also be materially totally different from these expressed or implied by these forward-looking statements. Some components that would trigger precise outcomes to differ embody our skill to display the efficacy and security of our drug candidates; the medical outcomes for our drug candidates, which can not assist additional improvement or advertising and marketing approval; actions of regulatory companies, which can have an effect on the initiation, timing and progress of medical trials and advertising and marketing approval; our skill to obtain industrial success for our drug candidates, if accredited; our restricted working historical past and our skill to receive extra funding for operations and to full the event and commercialization of our drug candidates; and different dangers and uncertainties set forth in “Risk Factors” in our most up-to-date Annual Report on Form 10-Ok and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and related statements replicate our beliefs and opinions on the related topic. These statements are primarily based upon info out there to us as of the date of this press launch, and whereas we consider such info kinds an inexpensive foundation for such statements, such info could also be restricted or incomplete, and our statements shouldn’t be learn to point out that we have now performed an exhaustive inquiry into, or evaluate of, all doubtlessly out there related info. These statements are inherently unsure and you’re cautioned not to rely unduly upon these statements. All info on this press launch is as of the date of this press launch. The info contained in any web site referenced herein shouldn’t be, and shall not be deemed to be, a part of or integrated into this press launch.
Source: Clene Inc.
